Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

99.14EUR
21 Jul 2017
Change (% chg)

€-1.51 (-1.50%)
Prev Close
€100.65
Open
€100.60
Day's High
€101.00
Day's Low
€98.77
Volume
650,422
Avg. Vol
390,105
52-wk High
€115.20
52-wk Low
€90.00

MRCG.DE

Chart for MRCG.DE

About

Merck KGaA is a Germany-based company engaged in the pharmaceutical industry. The Company operates through four business segments: Merck Serono; Consumer Health; Merck Millipore, and Performance Materials. Within the Merck Serono division, the Company focuses on therapeutic areas and prescription drugs of chemical and biotechnol... (more)

Overall

Beta: 1.02
Market Cap(Mil.): €12,813.08
Shares Outstanding(Mil.): 129.24
Dividend: 1.20
Yield (%): 1.21

Financials

  MRCG.DE Industry Sector
P/E (TTM): 27.63 11.79 15.85
EPS (TTM): 3.59 -- --
ROI: 5.48 -10.04 -8.31
ROE: 11.76 -9.89 -7.95

BRIEF-Merck KGaA and Pfizer: CHMP recommends approval of avelumab

* EMA’S CHMP ISSUES POSITIVE OPINION FOR AVELUMAB FOR THE TREATMENT OF METASTATIC MERKEL CELL CARCINOMA

Jul 21 2017

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.

Jul 21 2017

Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval

July 21 European regulators on Friday recommended approving Pfizer Inc and Merck KGaA's immuno-oncology drug Bavencio to treat a rare type of skin cancer called Merkel cell carcinoma.

Jul 21 2017

BRIEF-Merck KGaA refines Western European Life Science Production site network

* REFINES WESTERN EUROPEAN LIFE SCIENCE PRODUCTION SITE NETWORK

Jul 12 2017

EU charges Merck KGaA, GE, Canon of misleading merger info

BRUSSELS, July 6 EU antitrust regulators accused German drugmaker Merck KGaA, General Electric and Japan's Canon of providing misleading information during their merger deals, as regulators stepped up their crackdown on such practices.

Jul 06 2017

Germany's Merck gets EU backing for oral MS drug

(This June 23 story corrects second paragraph to show that the recommendation is to approve the relapsing forms, not the relapsing-remitting form of MS.)

Jun 24 2017

CORRECTED-Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

Jun 24 2017

BRIEF-EMA recommends approval of Merck's multiple sclerosis drug

* EU Medicines Agency recommends approval of Merck KGAA multiple sclerosis drug

Jun 23 2017

BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer

* Effector Therapeutics to collaborate with Pfizer and Merck KGAA to evaluate a novel immuno-oncology combination in microsatellite stable colorectal cancer

Jun 20 2017

BRIEF-Merck awarded first CRISPR patent by Australian patent office

* Awarded first CRISPR patent by Australian patent office Further company coverage:

Jun 14 2017

Earnings vs. Estimates